2024 Evexias / Farmakeio settlement

This is one entry from the TitrateLab Vendor Graveyard, a dated, primary-source archive of peptide-market shutdowns, exit scams, and enforcement actions. Documented as September 2024. Sources for this entry are named inline below and numbered in full on the parent archive page.

The settlement in litigation challenging the 2023 Category 2 reclassification. As part of the settlement, the FDA agreed to a PCAC review of certain peptides, a partial concession that created the procedural path to the 2026 Category 1 restoration push. Without this settlement, no July 23, 2026 PCAC meeting.

← Back to the full Vendor Graveyard

Every verified shutdown, exit scam, and FDA action, 2018–2026, in one dated archive.